Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.
The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Researchers at the Weill Institute for Cell and Molecular Biology have uncovered new evidence that two major types of gene-controlling DNA sequences, promoters and enhancers, operate with a shared ...
New York’s Finger Lakes region, with its deep lakes, rolling hills, and unpredictable weather, sets the pace for farmers. In some years, the average last frost arrives in mid-April, while in others it ...
Durham-based Precision BioSciences, a gene-editing company, has received regulatory clearance to begin a clinical study of its potential treatment for Duchenne muscular dystrophy (DMD), a rare ...
From carrying a first-aid kit in first grade to launching a transformative preventive cardiology program, a Rutgers Health ...
The Khazar theory has a long history but was largely discredited with the advent of DNA analysis. Yet it has grown in ...
Columnist Dennis Sun writes, "Higher beef prices and improved genetics are rewriting the dairy industry. Older dairy cows producing milk at higher ...
Duckweed is the fastest-growing flowering plant, but new knowledge of duckweed genetics discovered by Adelaide University researchers could lead to even faster growing rates. The research team, led by ...
CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ecological governance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results